

Effective Date: 9/01/2018
Reviewed: 4/2019, 1/2020, 3/2021, 6/2022, 4/2023, 11/2023, 5/2024, 4/2025, 1/2026
Scope: Medicaid

Corticotropin-ACTH:

Acthar Gel (repository corticotropin injection), Cortrophin Gel (repository corticotropin injection)

POLICY

I. CRITERIA FOR APPROVAL

An authorization of 1 month may be granted when all the following criteria are met:

- A. Member is less than 24 months old and has a diagnosis of infantile spasms (West Syndrome);
- B. Must be used as monotherapy;
- C. Documentation that member does not have a suspected congenital infection;
- D. If the request is for Acthar Gel, the member must have a documented contraindication, inadequate response or intolerance to Cortrophin Gel;
- E. Dose does not exceed 75 units/m² intramuscularly given twice daily for 2 weeks, then taper the dose over a 2-week period (e.g., 30 units/m² in the morning for 3 days; 15 units/m² in the morning for 3 days; 10 units/m² in the morning for 3 days; and 10 units/m² every other morning for 6 days).

II. COVERAGE DURATION

1 month

III. REFERENCES:

1. H.P. Acthar Gel [package insert]. Hazelwood, MO; Mallinckrodt Pharmaceuticals Inc; December 2025. Accessed January 2026.
2. Purified Cortrophin Gel [package insert]. Baudette, MN; ANI Pharmaceuticals, Inc.; August 2025. Accessed January 2026.